{
  "prompt": {
    "prompt": "Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\n\nFor each recommendation, specify:\n1. The type of recommendation:\n   - Additional information needed (history/examination/investigations)\n   - Improved patient advice (options/statistics/patient information)\n   - Different management plan\n2. The specific recommendation\n3. The reason for the recommendation (referencing the guideline)\n\nCategorize each recommendation by importance:\n- Very Important: Critical for patient safety or guideline compliance\n- Somewhat Important: Significant for optimal care but not critical\n- Less Important: Would improve care but not essential\n- Unimportant: Minor suggestions that could be considered\n\nFormat the response as follows:\n\n### Very Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Somewhat Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Less Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Unimportant Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\nClinical Note:\n**Dictation: Clinical Interaction – Abnormal Uterine Bleeding**  **Patient Details:**  \n- Name: [Fictional Name] Jane Doe  \n- Age: 36  \n- BMI: 18.9 (weight 52 kg, height 1.65 m)  \n- Gravida: 1, Para: 1 (prior full-term vaginal delivery)  \nLast Menstrual Period (LMP): 2 weeks ago (currently mid-cycle)  \n- Contraception: None currently  **History of Presenting Complaint:**  \nMs. Doe presents with a 4-month history of irregular menstrual bleeding. She reports episodes of heavy bleeding lasting 7–10 days, occurring every 2–3 weeks, with associated fatigue. She denies intermenstrual spotting but admits to occasional cramping. No history of post-coital bleeding. She has not been sexually active in the past year.  **Relevant Medical History:**  \nNo known bleeding disorders or thyroid dysfunction.  \nNo prior gynecological procedures (e.g., hysteroscopy, D&C).  \nNo history of fibroids or endometriosis.  \nNo chronic medical conditions.  **Medications & Allergies:**  \nOccasional ibuprofen for cramps (no regular medications).  \nNo known drug allergies.  **Social History:**  \nNon-smoker, occasional alcohol (1–2 units/week).  \nWorks as a teacher; moderate stress levels reported.  **Examination Findings:**  \n- General appearance: Pale conjunctivae (possible anemia).  \n- Abdomen: Soft, non-tender, no palpable masses.  \n- Speculum exam: Cervix appears normal, no visible lesions.  \n- Bimanual exam: Uterus anteverted, normal size, no adnexal tenderness.  **Notable Omissions (for testing purposes):**  \nNo documented assessment of iron studies or hemoglobin.  \nNo inquiry about family history of gynecological malignancies.  \nNo discussion of prior Pap smear history or HPV vaccination status.  \nPelvic ultrasound not yet performed.  **Impression:**  \nAbnormal uterine bleeding (AUB) in a premenopausal patient—differential includes ovulatory dysfunction (e.g., PCOS, thyroid disorder), endometrial polyp, or early perimenopausal changes.  **Management Plan:**  \n1. **Investigations:**  \n   Full blood count (FBC) to assess for anemia.  \n   TSH and prolactin to evaluate endocrine causes.  \n   Pelvic ultrasound to rule out structural pathology.  \n   (No endometrial biopsy arranged at this stage.)  2. **Symptomatic Relief:**  \n   Trial of tranexamic acid during heavy bleeding.  \n   Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.  3. **Follow-Up:**  \n   Review in 6 weeks with investigation results.  \n   If bleeding worsens or anemia confirmed, escalate to gynecology referral.  **Counseling Provided:**  \nReassured that AUB is common but requires evaluation.  \nAdvised to monitor bleeding patterns and report syncope or severe fatigue.  **Dictated by:** Dr. [Fictional Name] Smith  \n**Date:** [Fictional Date]  --*Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.*\n\n\n\nGuideline:\n[ID] gtg-2014-endometrial-hyperplasia-pdf\nTitle: GTG 2014 - Endometrial Hyperplasia.pdf\nContent: Management of Endometrial Hyperplasia\nRisk factors for endometrial hyperplasia should be identified and monitored. The WHO classification should be used for classification. Diagnosis and surveillance methods include endometrial sampling and hysteroscopy. Progestogens are effective in managing hyperplasia without atypia, with LNG-IUS being the first-line treatment. Treatment should last at least 6 months with follow-up biopsies. Surgical management may be considered in certain cases. Atypical hyperplasia should be managed with total hysterectomy. Women wishing to preserve fertility should be counseled about risks. HRT should be used cautiously. Women on adjuvant treatment for breast cancer should be monitored for hyperplasia. Endometrial hyperplasia confined to a polyp should be managed with complete removal. Regular surveillance is recommended. Management in women wishing to conceive should focus on achieving disease regression before attempting conception.\n\nThe 2014 WHO classification separates endometrial hyperplasia into two groups based on cytological atypia. Diagnosis requires histological examination. Surveillance methods include endometrial sampling and transvaginal ultrasound. Hysteroscopy may be necessary for further assessment. CT or MRI are not routinely recommended. Biomarkers have not been found to be clinically useful. Management of hyperplasia without atypia includes addressing reversible risk factors and considering progestogen treatment if regression does not occur. Weight loss and hormone therapy should be reviewed. Anovulatory cycles may regress with ovulation. Progestogen treatment may reduce the risk of progression to cancer. More evidence is needed to determine the appropriate management approach.\n\nMany women with endometrial hyperplasia may require treatment due to the risk of progression to cancer. The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens. Treatment should last for a minimum of 6 months to induce regression. Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge. Surgical management, such as hysterectomy, should be considered if there is no regression after 12 months of treatment or if there is relapse. A laparoscopic approach to hysterectomy is preferred. Endometrial ablation is not recommended. Annual endometrial biopsies can be considered for high-risk women. Ultimately, treatment decisions should be based on individual factors and patient preferences.\n\nEndometrial ablation is not recommended for atypical hyperplasia, as complete endometrial destruction cannot be guaranteed, and there is a risk of tissue regeneration. Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression. In cases where fertility preservation is desired or surgery is not suitable, first-line treatment with LNG-IUS is recommended, with oral progestogens as an alternative. Women should be counselled about the risks of fertility-sparing therapy, including the potential for cancer progression. Follow-up for women not undergoing hysterectomy should include routine endometrial surveillance with biopsies every 3 months until negative results are obtained. Women with atypical hyperplasia who wish to conceive should achieve disease regression before attempting to conceive and may consider assisted reproduction for higher live birth rates and to prevent relapse. It is important to monitor disease regression and consider referral to a fertility specialist for further assessment and treatment options.\n\n- A small trial showed that LNG-IUS treatment was more effective than observation alone in regressing simple hyperplasia and improving pregnancy rates in women with PCOS.\n- Hysterectomy is recommended for women with atypical endometrial hyperplasia once fertility is no longer required.\n- Systemic estrogen-only HRT should not be used in women with a uterus.\n- Women with endometrial hyperplasia on HRT should consider switching to continuous progestogen intake using LNG-IUS or continuous combined HRT.\n- Tamoxifen users should be aware of the increased risk of endometrial hyperplasia and cancer.\n- Aromatase inhibitors do not increase the risk of endometrial pathology or vaginal bleeding.\n- LNG-IUS may reduce the incidence of endometrial polyps and hyperplasia in women on tamoxifen.\n- Women with endometrial hyperplasia while on tamoxifen should reassess the need for tamoxifen with their oncologist.\n- Complete removal of endometrial polyps is recommended for management.\n- Recommendations for future research include evaluating the role of biomarkers in diagnosing endometrial hyperplasia and studying the effect of weight loss on regression of the condition.\n- Auditable topics include advising weight loss for obese women with endometrial hyperplasia and ensuring appropriate follow-up biopsies.\n- Useful links and support groups for endometrial hyperplasia.\n\nAccuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Investigation of post-menopausal bleeding. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. Asymptomatic endometrial thickening. Endometrial thickness screening in premenopausal women with abnormal uterine bleeding. Long-term Consequences of Polycystic Ovary Syndrome. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Diagnostic dilation and curettage: a reappraisal. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. A randomised trial comparing the H Pipelle with the standard Pipelle for endometrial sampling at ‘no-touch’ hysteroscopy. Ambulatory hysteroscopy. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. The behavior of endometrial hyperplasia: a prospective study. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women. Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Endometrial histology in severely obese bariatric surgery candidates: an exploratory analysis. Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists. Phytoestrogen consumption and endometrial cancer risk: a population-based case–control study. Histopathological findings of the endometrium in patients with dysfunctional uterine bleeding. Ovarian cysts in postmenopausal women. Management of suspected ovarian masses in premenopausal women. Inhibin as a marker for granulosa cell tumor. Granulosa cell tumor of the ovary. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in the treatment of simple endometrial hyperplasia without atypia. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia. Levonorgestrel-releasing intrauterine system is an efficient therapeutic modality for simple endometrial hyperplasia. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Levonorgestrel-releasing intrauterine system as an effective treatment option for endometrial hyperplasia. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Supracervical hyster\n\nLong-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121:709–16. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil Steril 1999;72:740–3. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2012; 207:266.e1–12. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010;116:365–73. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol 2012;124:542–8. American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol 2015;125:1006–26. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013;129:7–11. Fertility problems: assessment and treatment. NICE clinical guideline 156. Manchester: NICE; 2013. Efficacy of the levonorgestrel-releasing intrauterine system on IVF-ET outcomes in PCOS with simple endometrial hyperplasia. Reprod Sci 2015;22:758–66. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA1996;275:370–5.\n\nCommittee members from various locations contributed to the development of the guideline. The final version is the responsibility of the Guidelines Committee of the RCOG.",
    "system_prompt": "You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.",
    "guideline_id": "gtg-2014-endometrial-hyperplasia-pdf",
    "guideline_title": "GTG 2014 - Endometrial Hyperplasia.pdf"
  },
  "response": "Here is the analysis of the clinical note against the provided guideline (GTG 2014 - Endometrial Hyperplasia) with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document family history of gynecological malignancies and prior Pap smear/HPV vaccination status.  \n   Reason: The guideline emphasizes identifying risk factors for endometrial hyperplasia (e.g., family history of malignancies). Missing this information could delay diagnosis of high-risk cases.  \n\n2. **Different management plan** - Include endometrial biopsy or sampling in the initial workup, especially given the patient's prolonged (4-month) history of irregular bleeding.  \n   Reason: The guideline recommends histological examination for diagnosis of endometrial hyperplasia. Transvaginal ultrasound alone is insufficient to rule out hyperplasia/cancer.  \n\n3. **Additional information needed** - Assess hemoglobin/iron studies given clinical signs of anemia (pale conjunctivae).  \n   Reason: The guideline highlights anemia as a key complication of abnormal uterine bleeding (AUB) that requires management.  \n\n### Somewhat Important Recommendations  \n1. **Improved patient advice** - Counsel the patient about weight management (BMI 18.9 suggests underweight status, which can contribute to anovulation/AUB).  \n   Reason: The guideline notes that addressing reversible risk factors (e.g., weight extremes) is part of managing AUB/hyperplasia.  \n\n2. **Different management plan** - Consider LNG-IUS (levonorgestrel IUD) as first-line treatment if hyperplasia is confirmed, rather than starting with COCP.  \n   Reason: The guideline strongly recommends LNG-IUS as first-line for hyperplasia without atypia due to higher efficacy and fewer side effects vs. oral progestogens.  \n\n3. **Additional information needed** - Document prior ovulation status or evidence of anovulation (e.g., irregular cycles, PCOS features).  \n   Reason: The guideline differentiates management based on ovulatory dysfunction vs. structural causes.  \n\n### Less Important Recommendations  \n1. **Improved patient advice** - Provide written information on endometrial hyperplasia/AUB resources.  \n   Reason: The guideline lists patient support groups/resources, which improve adherence and understanding.  \n\n2. **Additional information needed** - Consider adding CA-125 if risk factors for malignancy are identified later.  \n   Reason: The guideline mentions biomarkers (though not routinely recommended) may be considered in high-risk cases.  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Discuss stress reduction techniques given her reported moderate stress.  \n   Reason: While stress can exacerbate AUB, the guideline does not prioritize this in management.  \n\n---  \n**Key Gaps:**  \n- No endometrial sampling despite prolonged AUB (critical for ruling out hyperplasia).  \n- LNG-IUS not discussed as a potential treatment option.  \n- Incomplete risk stratification (family history, cancer screening history).  \n\n**Alignment Strengths:**  \n- Appropriate initial tests (FBC, TSH, pelvic ultrasound).  \n- Consideration of COCP for cycle regulation (acceptable for AUB without confirmed hyperplasia).  \n- Planned follow-up timeline (6 weeks).  \n\nThe note would benefit most from adding endometrial sampling and explicit documentation of risk factors per the guideline.",
  "endpoint": "analyzeNoteAgainstGuideline",
  "timestamp": "2025-06-09T08-53-37",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\\n\\nFor each recommendation, specify:\\n1. The type of recommendation:\\n   - Additional information needed (history/examination/investigations)\\n   - Improved patient advice (options/statistics/patient information)\\n   - Different management plan\\n2. The specific recommendation\\n3. The reason for the recommendation (referencing the guideline)\\n\\nCategorize each recommendation by importance:\\n- Very Important: Critical for patient safety or guideline compliance\\n- Somewhat Important: Significant for optimal care but not critical\\n- Less Important: Would improve care but not essential\\n- Unimportant: Minor suggestions that could be considered\\n\\nFormat the response as follows:\\n\\n### Very Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Somewhat Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Less Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Unimportant Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\nClinical Note:\\n**Dictation: Clinical Interaction – Abnormal Uterine Bleeding**  **Patient Details:**  \\n- Name: [Fictional Name] Jane Doe  \\n- Age: 36  \\n- BMI: 18.9 (weight 52 kg, height 1.65 m)  \\n- Gravida: 1, Para: 1 (prior full-term vaginal delivery)  \\nLast Menstrual Period (LMP): 2 weeks ago (currently mid-cycle)  \\n- Contraception: None currently  **History of Presenting Complaint:**  \\nMs. Doe presents with a 4-month history of irregular menstrual bleeding. She reports episodes of heavy bleeding lasting 7–10 days, occurring every 2–3 weeks, with associated fatigue. She denies intermenstrual spotting but admits to occasional cramping. No history of post-coital bleeding. She has not been sexually active in the past year.  **Relevant Medical History:**  \\nNo known bleeding disorders or thyroid dysfunction.  \\nNo prior gynecological procedures (e.g., hysteroscopy, D&C).  \\nNo history of fibroids or endometriosis.  \\nNo chronic medical conditions.  **Medications & Allergies:**  \\nOccasional ibuprofen for cramps (no regular medications).  \\nNo known drug allergies.  **Social History:**  \\nNon-smoker, occasional alcohol (1–2 units/week).  \\nWorks as a teacher; moderate stress levels reported.  **Examination Findings:**  \\n- General appearance: Pale conjunctivae (possible anemia).  \\n- Abdomen: Soft, non-tender, no palpable masses.  \\n- Speculum exam: Cervix appears normal, no visible lesions.  \\n- Bimanual exam: Uterus anteverted, normal size, no adnexal tenderness.  **Notable Omissions (for testing purposes):**  \\nNo documented assessment of iron studies or hemoglobin.  \\nNo inquiry about family history of gynecological malignancies.  \\nNo discussion of prior Pap smear history or HPV vaccination status.  \\nPelvic ultrasound not yet performed.  **Impression:**  \\nAbnormal uterine bleeding (AUB) in a premenopausal patient—differential includes ovulatory dysfunction (e.g., PCOS, thyroid disorder), endometrial polyp, or early perimenopausal changes.  **Management Plan:**  \\n1. **Investigations:**  \\n   Full blood count (FBC) to assess for anemia.  \\n   TSH and prolactin to evaluate endocrine causes.  \\n   Pelvic ultrasound to rule out structural pathology.  \\n   (No endometrial biopsy arranged at this stage.)  2. **Symptomatic Relief:**  \\n   Trial of tranexamic acid during heavy bleeding.  \\n   Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.  3. **Follow-Up:**  \\n   Review in 6 weeks with investigation results.  \\n   If bleeding worsens or anemia confirmed, escalate to gynecology referral.  **Counseling Provided:**  \\nReassured that AUB is common but requires evaluation.  \\nAdvised to monitor bleeding patterns and report syncope or severe fatigue.  **Dictated by:** Dr. [Fictional Name] Smith  \\n**Date:** [Fictional Date]  --*Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.*\\n\\n\\n\\nGuideline:\\n[ID] gtg-2014-endometrial-hyperplasia-pdf\\nTitle: GTG 2014 - Endometrial Hyperplasia.pdf\\nContent: Management of Endometrial Hyperplasia\\nRisk factors for endometrial hyperplasia should be identified and monitored. The WHO classification should be used for classification. Diagnosis and surveillance methods include endometrial sampling and hysteroscopy. Progestogens are effective in managing hyperplasia without atypia, with LNG-IUS being the first-line treatment. Treatment should last at least 6 months with follow-up biopsies. Surgical management may be considered in certain cases. Atypical hyperplasia should be managed with total hysterectomy. Women wishing to preserve fertility should be counseled about risks. HRT should be used cautiously. Women on adjuvant treatment for breast cancer should be monitored for hyperplasia. Endometrial hyperplasia confined to a polyp should be managed with complete removal. Regular surveillance is recommended. Management in women wishing to conceive should focus on achieving disease regression before attempting conception.\\n\\nThe 2014 WHO classification separates endometrial hyperplasia into two groups based on cytological atypia. Diagnosis requires histological examination. Surveillance methods include endometrial sampling and transvaginal ultrasound. Hysteroscopy may be necessary for further assessment. CT or MRI are not routinely recommended. Biomarkers have not been found to be clinically useful. Management of hyperplasia without atypia includes addressing reversible risk factors and considering progestogen treatment if regression does not occur. Weight loss and hormone therapy should be reviewed. Anovulatory cycles may regress with ovulation. Progestogen treatment may reduce the risk of progression to cancer. More evidence is needed to determine the appropriate management approach.\\n\\nMany women with endometrial hyperplasia may require treatment due to the risk of progression to cancer. The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens. Treatment should last for a minimum of 6 months to induce regression. Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge. Surgical management, such as hysterectomy, should be considered if there is no regression after 12 months of treatment or if there is relapse. A laparoscopic approach to hysterectomy is preferred. Endometrial ablation is not recommended. Annual endometrial biopsies can be considered for high-risk women. Ultimately, treatment decisions should be based on individual factors and patient preferences.\\n\\nEndometrial ablation is not recommended for atypical hyperplasia, as complete endometrial destruction cannot be guaranteed, and there is a risk of tissue regeneration. Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression. In cases where fertility preservation is desired or surgery is not suitable, first-line treatment with LNG-IUS is recommended, with oral progestogens as an alternative. Women should be counselled about the risks of fertility-sparing therapy, including the potential for cancer progression. Follow-up for women not undergoing hysterectomy should include routine endometrial surveillance with biopsies every 3 months until negative results are obtained. Women with atypical hyperplasia who wish to conceive should achieve disease regression before attempting to conceive and may consider assisted reproduction for higher live birth rates and to prevent relapse. It is important to monitor disease regression and consider referral to a fertility specialist for further assessment and treatment options.\\n\\n- A small trial showed that LNG-IUS treatment was more effective than observation alone in regressing simple hyperplasia and improving pregnancy rates in women with PCOS.\\n- Hysterectomy is recommended for women with atypical endometrial hyperplasia once fertility is no longer required.\\n- Systemic estrogen-only HRT should not be used in women with a uterus.\\n- Women with endometrial hyperplasia on HRT should consider switching to continuous progestogen intake using LNG-IUS or continuous combined HRT.\\n- Tamoxifen users should be aware of the increased risk of endometrial hyperplasia and cancer.\\n- Aromatase inhibitors do not increase the risk of endometrial pathology or vaginal bleeding.\\n- LNG-IUS may reduce the incidence of endometrial polyps and hyperplasia in women on tamoxifen.\\n- Women with endometrial hyperplasia while on tamoxifen should reassess the need for tamoxifen with their oncologist.\\n- Complete removal of endometrial polyps is recommended for management.\\n- Recommendations for future research include evaluating the role of biomarkers in diagnosing endometrial hyperplasia and studying the effect of weight loss on regression of the condition.\\n- Auditable topics include advising weight loss for obese women with endometrial hyperplasia and ensuring appropriate follow-up biopsies.\\n- Useful links and support groups for endometrial hyperplasia.\\n\\nAccuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Investigation of post-menopausal bleeding. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. Asymptomatic endometrial thickening. Endometrial thickness screening in premenopausal women with abnormal uterine bleeding. Long-term Consequences of Polycystic Ovary Syndrome. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Diagnostic dilation and curettage: a reappraisal. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. A randomised trial comparing the H Pipelle with the standard Pipelle for endometrial sampling at ‘no-touch’ hysteroscopy. Ambulatory hysteroscopy. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. The behavior of endometrial hyperplasia: a prospective study. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women. Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Endometrial histology in severely obese bariatric surgery candidates: an exploratory analysis. Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists. Phytoestrogen consumption and endometrial cancer risk: a population-based case–control study. Histopathological findings of the endometrium in patients with dysfunctional uterine bleeding. Ovarian cysts in postmenopausal women. Management of suspected ovarian masses in premenopausal women. Inhibin as a marker for granulosa cell tumor. Granulosa cell tumor of the ovary. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in the treatment of simple endometrial hyperplasia without atypia. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia. Levonorgestrel-releasing intrauterine system is an efficient therapeutic modality for simple endometrial hyperplasia. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Levonorgestrel-releasing intrauterine system as an effective treatment option for endometrial hyperplasia. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Supracervical hyster\\n\\nLong-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121:709–16. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil Steril 1999;72:740–3. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2012; 207:266.e1–12. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010;116:365–73. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol 2012;124:542–8. American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol 2015;125:1006–26. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013;129:7–11. Fertility problems: assessment and treatment. NICE clinical guideline 156. Manchester: NICE; 2013. Efficacy of the levonorgestrel-releasing intrauterine system on IVF-ET outcomes in PCOS with simple endometrial hyperplasia. Reprod Sci 2015;22:758–66. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA1996;275:370–5.\\n\\nCommittee members from various locations contributed to the development of the guideline. The final version is the responsibility of the Guidelines Committee of the RCOG.\",\n  \"system_prompt\": \"You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.\",\n  \"guideline_id\": \"gtg-2014-endometrial-hyperplasia-pdf\",\n  \"guideline_title\": \"GTG 2014 - Endometrial Hyperplasia.pdf\"\n}\n\nA: Here is the analysis of the clinical note against the provided guideline (GTG 2014 - Endometrial Hyperplasia) with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document family history of gynecological malignancies and prior Pap smear/HPV vaccination status.  \n   Reason: The guideline emphasizes identifying risk factors for endometrial hyperplasia (e.g., family history of malignancies). Missing this information could delay diagnosis of high-risk cases.  \n\n2. **Different management plan** - Include endometrial biopsy or sampling in the initial workup, especially given the patient's prolonged (4-month) history of irregular bleeding.  \n   Reason: The guideline recommends histological examination for diagnosis of endometrial hyperplasia. Transvaginal ultrasound alone is insufficient to rule out hyperplasia/cancer.  \n\n3. **Additional information needed** - Assess hemoglobin/iron studies given clinical signs of anemia (pale conjunctivae).  \n   Reason: The guideline highlights anemia as a key complication of abnormal uterine bleeding (AUB) that requires management.  \n\n### Somewhat Important Recommendations  \n1. **Improved patient advice** - Counsel the patient about weight management (BMI 18.9 suggests underweight status, which can contribute to anovulation/AUB).  \n   Reason: The guideline notes that addressing reversible risk factors (e.g., weight extremes) is part of managing AUB/hyperplasia.  \n\n2. **Different management plan** - Consider LNG-IUS (levonorgestrel IUD) as first-line treatment if hyperplasia is confirmed, rather than starting with COCP.  \n   Reason: The guideline strongly recommends LNG-IUS as first-line for hyperplasia without atypia due to higher efficacy and fewer side effects vs. oral progestogens.  \n\n3. **Additional information needed** - Document prior ovulation status or evidence of anovulation (e.g., irregular cycles, PCOS features).  \n   Reason: The guideline differentiates management based on ovulatory dysfunction vs. structural causes.  \n\n### Less Important Recommendations  \n1. **Improved patient advice** - Provide written information on endometrial hyperplasia/AUB resources.  \n   Reason: The guideline lists patient support groups/resources, which improve adherence and understanding.  \n\n2. **Additional information needed** - Consider adding CA-125 if risk factors for malignancy are identified later.  \n   Reason: The guideline mentions biomarkers (though not routinely recommended) may be considered in high-risk cases.  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Discuss stress reduction techniques given her reported moderate stress.  \n   Reason: While stress can exacerbate AUB, the guideline does not prioritize this in management.  \n\n---  \n**Key Gaps:**  \n- No endometrial sampling despite prolonged AUB (critical for ruling out hyperplasia).  \n- LNG-IUS not discussed as a potential treatment option.  \n- Incomplete risk stratification (family history, cancer screening history).  \n\n**Alignment Strengths:**  \n- Appropriate initial tests (FBC, TSH, pelvic ultrasound).  \n- Consideration of COCP for cycle regulation (acceptable for AUB without confirmed hyperplasia).  \n- Planned follow-up timeline (6 weeks).  \n\nThe note would benefit most from adding endometrial sampling and explicit documentation of risk factors per the guideline.\n\n--- Token Usage Report ---\nPrompt tokens: 3063\nCompletion tokens: 650\nTotal tokens: 3713\nEstimated cost: $0.001857",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 3063,
    "completion_tokens": 650,
    "total_tokens": 3713,
    "estimated_cost_usd": 0.0018565
  }
}